Shots:

• The reimbursement of Kisqali is a testament to the ongoing need for public access to the treatment. The Canadian Province- Quebec will reimburse Kisqali + Letrozole under the public drug program as 1L treatment for HR+- HER2-negative advanced or metastatic breast cancer in post-menopausal women
• Novartis will collaborate with remaining province and territories in Canada ensuring the access of Kisqali to the patients & healthcare providers
• Kisqali is a selective cyclin-dependent kinase inhibitor- act by inhibiting CDK4/6 thus ensure that cancer cells do not continue to replicate uncontrollably and was developed by Novartis Institutes for BioMedical Research in collaboration with Astex Pharmaceuticals

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Pharmaceutical Technology